Calming the (Cytokine) storm: Dimethyl fumarate as a therapeutic candidate for covid-19
Download
Download
DownloadPreview
pharmaceuticals-14-00015.pdf
- Published Version
(1MB)
| Preview
Available under license: Creative Commons Attribution
Export
Timpani, Cara 
ORCID: 0000-0003-4567-4319 and Rybalka, Emma ORCID: 0000-0002-4854-0036
(2021)
Calming the (Cytokine) storm: Dimethyl fumarate as a therapeutic candidate for covid-19.
Pharmaceuticals, 14 (1).
pp. 1-15.
ISSN 1424-8247
(In Press)
Abstract
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.
Dimensions Badge
Altmetric Badge
| Item type | Article |
| URI | https://vuir.vu.edu.au/id/eprint/42094 |
| DOI | 10.3390/ph14010015 |
| Official URL | https://www.mdpi.com/1424-8247/14/1/15 |
| Subjects | Historical > FOR Classification > 0601 Biochemistry and Cell Biology Historical > FOR Classification > 1109 Neurosciences Current > Division/Research > Institute for Health and Sport |
| Keywords | severe acute respiratory syndrome coronavirus type-2, SARS-CoV-2, COVID-19 pandemic, Dimethyl fumarate, DMF, approved drug, immunomodulatory properties, anti-oxidative properties, anti-inflammatory properties, hyperinflammation |
| Citations in Scopus | 21 - View on Scopus |
| Download/View statistics | View download statistics for this item |
CORE (COnnecting REpositories)